Multidrug Resistance Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Screening of Multidrug Resistant Bacteria, and the Clinical Implication for the Patient
Conditions: Multi-antibiotic Resistance Interventions: Other: (exposure of) MDR carriage Sponsors: Region Skane; Lund University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials

A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT
DiscussionPROSPECT aims to assess the safety and efficacy of a BDQ-containing SCR MDR-TB treatment at seventeen sites across China, while also providing high-quality data to guide SCRs administration under the direction of the China National Tuberculosis Program for MDR-TB. Additionally, PROSPECT will explore the potential benefits of extending the administration of the 9-month BDQ-containing SCR for participants without sputum conversion by week 16.Trial registrationClinicalTrials.gov NCT05306223. Prospectively registered on 16 March 2022 athttps://clinicaltrials.gov/ct2/show/NCT05306223?term=NCT05306223&draw=1&ra...
Source: Trials - April 1, 2024 Category: Research Source Type: clinical trials

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
Conditions: Antimicrobial Drug Resistance; Antibiotic Resistant Infection; Clostridium Difficile; Carbapenem-Resistant Enterobacteriaceae Infection; Extended Spectrum Beta-Lactamase Producing Bacteria Infection; Vancomycin Resistant Enterococci Infection; Carbapenem Resistant Bacterial Infection; Vancomycin-Resistant Enterococcal Infection Sponsors: The Methodist Hospital Research Institute; National Institute of Allergy and Infectious Diseases (NIAID); M.D. Anderson Cancer Center; Baylor College of Medicine; University of Houston; William Marsh Rice University; The University of Texas Health Science Center, Houston Recrui...
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials

Antibiotics Resistance Gene in Healthcare Workers
Conditions: Multidrug Resistant Bacterial Infection Interventions: Other: metagenomics Sponsors: First Affiliated Hospital of Zhejiang University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials

Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy
The objective of this study is to evaluate the safety, efficacy, and appropriate dosing of a 4-month regimen of QBS in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary TB in comparison with the 6-month standard treatment (i.e., rifampicin, isoniazid, ethambutol, and pyrazinamide).MethodsThis phase 2b/c, open-label, randomized, parallel group, dose-finding trial will enroll approximately 120 participants (including no more than 15% with human immunodeficiency virus [HIV] coinfection) aged ≥ 18 to ≤ 65 years at screening with newly diagnosed pulmonary drug-sensitive TB from ~8 si...
Source: Trials - January 19, 2024 Category: Research Source Type: clinical trials

Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial
DiscussionThis trial will evaluate the contribution of different modes of adherence support on MDR-TB and HIV outcomes with WHO-recommended all-oral MDR-TB regimens and ART in a high-burden operational setting. We will also assess the utility of a DSD framework to pragmatically adjust levels of MDR-TB and HIV treatment support.Trial registrationClinicalTrials.gov NCT05633056. Registered on 1 December 2022 (Source: Trials)
Source: Trials - December 1, 2023 Category: Research Source Type: clinical trials

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
DiscussionThis internally controlled study of shortened treatment for pre-XDR TB will provide urgently needed data and evidence for clinical and policy decision-making around the treatment of pre-XDR TB with a four-drug, all-oral, shortened regimen.Trial registrationClinicalTrials.Gov NCT03896685. Registered on 1 April 2018; the record was last updated for study protocol version 4.3 on 17 March 2023. (Source: Trials)
Source: Trials - November 30, 2023 Category: Research Source Type: clinical trials

Comparison of Epithelial Lining Fluid and Blood Pharmacokinetics and Pharmacodynamics of Intravenous and Intravenous Plus Nebulized Polymyxin B in Multidrug Resistant Bacteria Ventilator-associated Pneumonia Patients
Conditions: Polymyxin B; Ventilator-associated Pneumonia; Multidrug Resistant Bacterial Infection; Pharmacogenomic Drug Interaction Interventions: Drug: nebulized polymyxin B Sponsors: Southeast University, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 11, 2023 Category: Research Source Type: clinical trials

NIH Investigates Multidrug-Resistant Bacterium Emerging in Community Settings
September 6, 2023 -- New“hypervirulent” strains of the bacterium Klebsiella pneumoniae have emerged in healthy people in community settings, prompting a National Institutes of Health research group to investigate how the human immune... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 6, 2023 Category: Pharmaceuticals Source Type: clinical trials

Risk Factors for Multidrug Resistant Bacteria at ICU Admission
Condition: Multi Drug Resistant Bacteria Intervention: Diagnostic Test: Identification o Multi Drug Resistant Bacteria Sponsor: José Raimundo Araujo de Azevedo Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials